The Chiesi Ventures fund is focused on investing in rare and orphan diseases, with the goal of contributing to the advancement of high quality research and development opportunities for therapies that can provide a hope for patients and their families. Pappas Specialized Fund Management is supporting Chiesi’s North American market expansion strategy by identifying the most promising investment opportunities, structuring investment transactions and overseeing portfolio company relationships. We’re using our network to help Chiesi expand its network – among universities, venture capital investors, rare disease patient organizations and entrepreneurial companies developing treatments for rare diseases.

Launched in 2014, Chiesi Ventures is actively seeking out investment opportunities in the field of rare and orphan diseases. We are especially interested in early-stage companies with “first in class” products or technologies that offer the potential to significantly extend patients’ lives and/or substantially improve the quality of patients’ lives. The Chiesi fund will consider a wide range of opportunities, from traditional small molecules and biologics, to gene therapies and cell therapies, to diagnostic and disease management technologies. Learn More.

“We are impressed by Pappas Capital’s life science and venture expertise and the specific commitment that the firm has made to the area of rare diseases.”

– Dr. Alberto Chiesi, President of the Chiesi Group


June 20, 2018 – Kezar Life Sciences Announces Pricing of Initial Public Offering

June 17, 2018 – Aura Biosciences Announces Update of Clinical Safety and Efficacy Data on Lead Candidate AU-011 for Choroidal Melanoma

December 21, 2017 – Aura Biosciences Completes $30 Million Series C Financing

July 25, 2017 – Kezar Life Sciences Announces Successful Completion of Phase 1a Study and Secures $50 Million in Series B Financing

April 4, 2017 – Sentien Biotechnologies, Inc. Announces $12 million Series A Financing

March 30, 2017 – Aura Biosciences Announces Initiation of Phase 1b Clinical Trial and Receipt of FDA Fast Track Designation for AU-011 for the Treatment of Primary Ocular Melanoma

February 6, 2017 – Aura Biosciences Receives FDA Clearance of Investigational New Drug Application for Light-activated AU-011 for the Treatment of Ocular Melanoma

November 16, 2016 – Chiesi Ventures Invests in Glycomine

October 14, 2015 – Chiesi Ventures Invests in Minoryx Therapeutics

March 5, 2015 – Chiesi Ventures Invests in Aura Biosciences